Immunovia Unveils Groundbreaking Findings at the AACR Conference
Immunovia, a company dedicated to improving diagnostics for pancreatic cancer, revealed significant findings from its model development study at a prestigious medical conference. This event brought together experts in cancer research, providing Immunovia the platform to present its work aimed at boosting early detection of pancreatic cancer.
Key Insights from the Model Development Study
The study showcased an innovative next-generation test specifically designed to identify stage 1 and 2 pancreatic cancer. Analyzing 623 patient samples, Immunovia demonstrated impressive advancements in the detection capacity of this test.
Biomarker Selection Methodology
Throughout the study, Immunovia outlined its systematic method for selecting vital biomarkers essential for the test. By employing a detailed algorithm, the company ensured that their test could accurately locate individuals at risk of developing pancreatic cancer, thus enhancing opportunities for early treatment.
Test Performance and Outcomes
The results highlighted an impressive test sensitivity of 85% and a specificity of 98%. These figures reveal that Immunovia’s test surpassed CA19-9, a commonly used biomarker, by 20 percentage points, setting a new benchmark in the field of pancreatic cancer diagnostics.
A Memorable Conference Experience
This esteemed gathering, organized by the American Association for Cancer Research (AACR), fostered collaboration among leading pancreatic cancer researchers and advocates. Immunovia expressed appreciation for the chance to share its findings, acknowledging the importance of rigorous scientific evaluation in promoting the adoption of its groundbreaking test.
Plans for Improving Early Detection
Norma Palma, PhD, Vice President of Clinical and Medical Affairs at Immunovia, emphasized the critical role of these studies in the path toward launching their next-generation test. Expected to debut next year, this test could significantly transform early detection methods for pancreatic cancer, potentially improving survival rates.
Dedication to Community Involvement
Immunovia is devoted to engaging with healthcare professionals and patient advocacy organizations, aiming to ensure their innovative test is accessible for those at high risk for pancreatic cancer. These initiatives promise closer collaboration with the healthcare community to raise awareness and improve testing accessibility.
About Immunovia's Objectives
The main goal of Immunovia AB is to enhance survival rates among pancreatic cancer patients through cutting-edge diagnostic solutions. By concentrating on straightforward blood-based testing methods, Immunovia strives to provide healthcare providers with the necessary tools to detect proteins and antibodies that signify pancreatic cancer in its early stages.
Market Potential and Implications
As the largest market for pancreatic cancer detection, the United States has an estimated 1.8 million individuals at increased risk. This population stands to gain significantly from regular surveillance testing, highlighting the urgent need for effective diagnostic strategies.
Contact Information
If you have any questions or need further information regarding Immunovia’s initiatives, please contact:
Jeff Borcherding
CEO and President
+46 70 911 56 08
Frequently Asked Questions
What was presented at the AACR conference?
Immunovia shared results from its model development study regarding a next-generation pancreatic cancer test.
What are the key performance metrics of the test?
The test has shown a sensitivity of 85% and a specificity of 98%.
What differentiates Immunovia's test from CA19-9?
Immunovia’s test has a sensitivity that outperforms CA19-9 by 20 percentage points, making it more reliable for early detection.
How is Immunovia engaging with the community?
Immunovia collaborates with healthcare providers and advocacy groups to enhance accessibility and awareness of their testing solutions.
What is Immunovia's focus moving forward?
The company's primary aim is to launch its next-generation test to better early detection and positively affect survival rates in pancreatic cancer patients.
